Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06574620 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

Study acronym: ACCELERATE
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 32 words Secondary endpoints: details revised at 1 of 5 entries · Publications: details revised at 24 of 25 entries Show 2 more changesShow less
    • Secondary endpoints: details revised at 1 of 5 entries
    • Publications: details revised at 24 of 25 entries
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 2025 to Nov 28, 2025 · Site details revisedv5 Show 2 more changesShow less
    • Start date changed from estimate of Oct 2025 to Nov 28, 2025
    • Site details revised
  3. Start date: Apr 2025 to Oct 2025 Interventions: Genetic testing (Genetic), Optional biopsy (Procedure) to Genetic testing (Genetic), Optional biopsy (Procedure), Tissue collection (Procedure)v4 Show 1 more changeShow less
    • Interventions: Genetic testing (Genetic), Optional biopsy (Procedure) to Genetic testing (Genetic), Optional biopsy (Procedure), Tissue collection (Procedure)
  4. Start date: Nov 2024 to Apr 2025v3
  5. Start date: Oct 2024 to Nov 2024 Publications reorderedv2 Show 1 more changeShow less
    • Publications reordered
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * Is it feasible to obtain genetic test results within a timeframe that can help inform treatment decisions for individuals with PDAC? * Can the genetic test results provide information about how a tumour will respond to or resist treatment? Participants will: * Receive standard chemotherapy to treat their cancer. * Provide samples of their blood, tissue, and fluid for genetic testing. * Visit the clinic every 4 weeks for check-ups and tests. * Complete questionnaires every 12 weeks.
Trial Details
NCT Number NCT06574620
Lead Sponsor British Columbia Cancer Agency
Collaborators: Terry Fox Research Institute, BC Cancer Foundation
Conditions Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov